The Burden of Non-Small Cells Lung Cancer (NSCLC) in First Line (1L) Treatment: Patterns of Care and Cost of Illness

Piedade, A; Goes, L; Castro, A.P.; Alves, AF; Minowa, E

doi:10.1016/j.jval.2014.08.2232

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among stage III group, chemotherapy combined with radiotherapy (concomitant or sequential) was the most frequently used treatment strategy (30.9%), followed by chemotherapy only (28.8%). This data is consistent with a previous analysis conducted in the Brazilian private healthcare system, which shows widespread use of platinum-based regimens (22,23). analyzed NSCLC patients in the private health sector from 2011 to 2014, and the use of a wide variety of systemic therapies was reported.…”

Section: B Asupporting

confidence: 93%

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study

Cerqueira,

Batista,

Almeida

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is still diagnosed at late stages in Brazil. The availability of newer treatment options has changed patient management, however, few real-world data have been published since then. This is a population-based retrospective cohort study that aims to evaluate the characteristics of stage III/IV NSCLC patients and their journey in the Brazilian private healthcare system. Patients aged ≥18 years, residing in Brazil who had their first medical appointment between 2016 and 2018 were included in the study. The sociodemographic and clinical characteristics of the patients and time intervals of interest were described. A total of 10,394 patients were analyzed. The majority of the patients were male (58.5%) with a median age of 64.0 (IQR = 58.0 – 71.0) years. In relation to characteristics of the disease, most of the tumors were characterized as adenocarcinomas (52.3%) and diagnosed at stage IV (72.2%). Most patients arrived at the hospital with an established NSCLC diagnosis, while 45.7% were diagnosed at the first medical appointment in the hospital or later. For patients who were diagnosed at the first medical appointment or later, a median interval of 15.0 (IQR = 6.0 – 33.0) days was observed between the first medical appointment and the diagnosis. The first treatment was given after a median of 25.0 (IQR = 6.0 – 49.0) days after diagnosis for patients without a prior diagnosis, and 57.0 (IQR: 33.0 – 98.0) days for patients with a prior diagnosis. The most common treatments were chemotherapy alone (33.8%), chemotherapy combined with radiotherapy (21.5%), radiotherapy alone (13.1%), adjuvant or neoadjuvant treatment (9.3%), surgery (3.3%), and immunotherapy (0.7%; alone or combined). At the end of follow-up (September, 2020), 52.3% of the patients had died. Despite having more treatment options in the private sector, data show that there is a need to improve access to technologies.

show abstract

Section: B Asupporting

confidence: 93%

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study

Cerqueira,

Batista,

Almeida

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Vários regimes quimioterápicos diferentes foram utilizados na prática clínica, incluindo tratamentos recentemente aprovados. Este estudo corrobora com estudos anteriormente publicados com objetivos semelhantes no Brasil e em outros países (de Castro et al, 2017;Piedade et al, 2014;Tanaka et al, 2016;Davis et al, 2015;Sacher et al, 2015;Solem et al, 2015a).…”

Section: Discussionunclassified

“…De fato, os estudos de dados do mundo real são os mais utilizados pelos órgãos de Avaliação de Tecnologia em Saúde (ATS) em todo o mundo (Stephens et al, 2012). No Brasil, poucos estudos descreveram padrões de tratamento de CPNPC avançados ( CPNPCa) com detalhes sobre o esquema de tratamento (Araujo et al, 2014;Martins & Pereira, 1999;Younes et al, 1992;de Castro et al, 2017;Lopes et al, 2015;Piedade et al, 2014;Tanaka et al, 2016). Além disso, dados sobre o uso de recursos e custos relacionados ao CPNPC são escassos, dificultando o desenvolvimento de estudos farmacoeconômicos locais.…”

Section: Introductionunclassified

Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em instituições brasileiras privadas

Baldotto¹,

Julian²,

Mascarenhas³

et al. 2018

JBES

View full text Add to dashboard Cite

RESUMOObjetivo: No Brasil, dados clínicos e custos econômicos do câncer de pulmão de não pequenas células (CPNPC) são escassos. Portanto, conduzimos este estudo para coletar dados de mundo real sobre padrões de tratamento e uso de recursos para CPNPC avançado ( CPNPCa) em pacientes em instituições privadas brasileiras. Métodos: Coletamos dados de prontuários de seis instituições privadas no Brasil. Os pacientes elegíveis tinham diagnóstico de CPNPC avançado ou recorrente (estágios IIIB e IV) entre janeiro de 2011 e julho de 2014, e haviam recebido pelo menos duas linhas de quimioterapia. Dados foram resumidos usando estatísticas descritivas e os custos foram estimados pela abordagem bottom-up. Resultados: Dos 430 pacientes selecionados, 152 foram elegíveis para coleta de dados. A idade mediana dos pacientes foi de 62 anos e 55,9% eram do sexo masculino. Entre os pacientes, 57,2% e 31,6% receberam três e quatro linhas de tratamento, respectivamente. Dezesseis e vinte regimes foram utilizados como tratamentos de primeira e segunda linha. Bevacizumabe + carboplatina + paclitaxel (n = 32; 21,1%) foi o mais frequente na primeira linha, enquanto docetaxel isolado (n = 36; 23,7%) foi o regime mais comum de segunda linha. Hospitalizações e visitas ao pronto-socorro foram registradas em 52% e 25% dos pacientes, respectivamente. O custo total da coorte foi de R$ 47. 692.195,1 (US$ 14.803.425,4). Conclusões: Os padrões de tratamento para pacientes com CPNPCa em instituições privadas brasileiras são heterogêneos. O alto uso e custos de recursos observados entre os pacientes da CPNPCa têm um impacto econômico significativo para o sistema de saúde privado brasileiro. ABSTRACTObjective: In Brazil, data on clinical and economic burden of non-small cell lung cancer (NSCLC) are scarce. Therefore, we conducted this study to gather real-world data on treatment patterns and resource use for advanced NSCLC (aNSCLC) patients in Brazilian private institutions. Methods: We collected data from medical charts from six private institutions in Brazil. Eligible patients were diagnosed with advanced or recurrent NSCLC (stages IIIB and IV) between January 2011 and July 2014, and had received at least two lines of chemotherapy. Data were summarized using descriptive statistics and costs estimated by bottom-up approach. Results: Out of 430 charts screened, 152 were eligible for data collection. Patients' median age was 62 years, 55.9% were male. Among patients, 57.2% são funcionários da Kantar Health. Os demais autores declaram não ter conflitos de interesse relevantes para a submissão do manuscrito. Este estudo foi patrocinado pela Bristol-Myers Squibb.Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em instituições brasileiras privadas Treatment patterns, resource use and cost-of-illness of advanced non-small lung cancer in Brazilian private institutions J Bras Econ Saúde 2018;10(2): 86-106Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em ins...

show abstract

The Burden of Non-Small Cells Lung Cancer (NSCLC) in First Line (1L) Treatment: Patterns of Care and Cost of Illness

Cited by 2 publications

References 0 publications

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study

Padrões de tratamento, uso de recursos e custo do câncer de pulmão de não pequenas células avançado em instituições brasileiras privadas

Contact Info

Product

Resources

About